These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 17427547)

  • 1. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study].
    Gür D; Mülazimoğlu L; Unal S;
    Mikrobiyol Bul; 2007 Jan; 41(1):1-9. PubMed ID: 17427547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
    Nagai K; Davies TA; Ednie LM; Bryskier A; Palavecino E; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3242-5. PubMed ID: 11600391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae.
    Kim NJ; Park SJ; Choi SH; Lee MS; Choo EJ; Kwak YG; Woo JH; Ryu J; Jeong JY; Kim YS
    Microb Drug Resist; 2005; 11(3):260-5. PubMed ID: 16201929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators.
    Shackcloth J; Williams L; Farrell DJ
    J Infect; 2004 Apr; 48(3):229-35. PubMed ID: 15001301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Banche G; Roana J; Allizond V; Andreotti S; Malabaila A; Li Vigni N; Mandras N; Scalas D; Tullio V; Carlone NA; Savoia D; Gaido E; Barbui A; Cuffini AM
    Lett Appl Microbiol; 2008 Oct; 47(4):309-14. PubMed ID: 19241525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P; Juvin ME; Tassin S; Bryskier A; Schito GC; Drugeon HB
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2999-3002. PubMed ID: 11036012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD; Rybak MJ
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
    Kays MB; Lisek CR; Denys GA
    Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004).
    Inoue M; Farrell DJ; Kaneko K; Akizawa K; Fujita S; Kaku M; Igari J; Yamaguchi K; Yamanaka K; Murase M; Asari S; Hirakata Y; Baba H; Itaha H
    Microb Drug Resist; 2008 Jun; 14(2):109-17. PubMed ID: 18500920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.
    Hsueh PR; Teng LJ; Lee CM; Huang WK; Wu TL; Wan JH; Yang D; Shyr JM; Chuang YC; Yan JJ; Lu JJ; Wu JJ; Ko WC; Chang FY; Yang YC; Lau YJ; Liu YC; Leu HS; Liu CY; Luh KT;
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2152-7. PubMed ID: 12821461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
    Jenkins SG; Brown SD; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A; Forsthuber S; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities.
    Ioannidou S; Tassios PT; Zachariadou L; Salem Z; Kanelopoulou M; Kanavaki S; Chronopoulou G; Petropoulou N; Foustoukou M; Pangalis A; Trikka-Graphakos E; Papafraggas E; Vatopoulos AC
    Clin Microbiol Infect; 2003 Jul; 9(7):704-7. PubMed ID: 12925112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics.
    Yamaguchi T; Hashikita G; Takahashi S; Itabashi A; Yamazaki T; Maesaki S
    J Infect Chemother; 2005 Oct; 11(5):262-4. PubMed ID: 16258826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001.
    Reinert RR; Lütticken R; Bryskier A; Al-Lahham A
    Antimicrob Agents Chemother; 2003 Feb; 47(2):489-93. PubMed ID: 12543648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
    Felmingham D; Reinert RR; Hirakata Y; Rodloff A
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():25-37. PubMed ID: 12239226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.